BioGraph 55

BioGraph 55 is a preclinical-stage biotechnology company developing next-generation B-cell therapies for autoimmune disease. Its lead program, B55-001, is a first-in-class bispecific antibody that selectively eliminates disease-driving B cells through a dual co-targeting mechanism of action. The approach is designed to drive deeper depletion of pathogenic B-cell populations that competing therapies miss while preserving broader immune function through avidity-driven selectivity, offering potential for transformative efficacy across multiple autoimmune indications. The company is backed by Pfizer Ventures and Red Tree Venture Capital.